METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for tough prostate cancer
Disease control CompletedThis phase II trial tested a combination of three drugs—carboplatin, cabazitaxel, and abiraterone—in 61 men with high-volume metastatic prostate cancer that still responds to hormone therapy. The goal was to see how many men had no cancer growth after one year. The study also tra…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Vaccine-Chemo combo shows promise against spread prostate cancer
Disease control CompletedThis study tested whether adding a prostate cancer vaccine (PROSTVAC) and chemotherapy (docetaxel) to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. 74 men with metastatic castration-sensitive prostate cancer took part. …
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Real-World data reveals treatment patterns for advanced prostate cancer
Knowledge-focused CompletedThis completed study examined how long men with metastatic castration-sensitive prostate cancer take newer hormonal therapies like abiraterone, apalutamide, and enzalutamide. Researchers analyzed Medicare claims data from over 3,000 men aged 65 and older. The goal was to describe…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC